Clinicogenomic characterization and targeted therapy efficacy in Chinese patients with NTRK fusion-positive thyroid cancer: a preliminary retrospective cohort study.
- 1Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- 2Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- 3Department of Nuclear Medicine, Peking Union Medical College Hospital and Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China.
Abstract
Neurotrophic receptor tyrosine kinase (NTRK) fusion-positive thyroid cancer is a rare but highly aggressive malignancy. These tumors exhibit potential responsiveness to TRK-inhibitor therapy; however, real-world clinical data in Chinese populations remain scarce, and clinical management for radioiodine-refractory cases remains incompletely defined. This study aims to characterize the clinicopathological features of Chinese patients and to evaluate the efficacy and safety of the NTRK targeted agent. A single-center retrospective analysis was conducted. Sixteen patients were identified from 253 thyroid cancer patients who received next-generation sequencing from January 2022 to March 2025 at our institution. Exclusion criteria included insufficient pathological material and incomplete clinical follow-up records. Baseline clinical, pathological, genomic, and treatment-related variables were retrospectively abstracted from medical records. Follow-up was performed via clinical visits and serial imaging examinations to assess treatment responses and adverse events. The age range of the 16 patients was 6-55 years, and the pathological diagnosis of all tumors was primary papillary carcinoma. Children (n=10) and female patients (n=11) accounted for the majority of the cohort. Distant metastases were present at initial diagnosis in 12 patients, among whom pulmonary metastasis was observed in 11 cases. All 10 patients with NTRK3 fusions harbored the ETV6 fusion partner, whereas common fusion partners for NTRK1-positive tumors included TPM3, IRF2BP2, and SFPQ. Postoperative radioactive iodine (RAI) treatment yielded poor responses, and radioiodine resistance developed frequently. Larotrectinib produced favorable clinical outcomes in patients with RAI-refractory disease and induced tumor cell redifferentiation in one adolescent patient, with no severe adverse reactions. This disease predominantly affects young Chinese patients and is characterized by strong invasiveness and frequent RAI resistance. Encouraging therapeutic responses were observed in TRK inhibitor-treated subgroup.
Related
- Development and preliminary clinical characterization of an MDT-defined surgical-window framework for complex pancreatic cancer: a retrospective cohort study.
- 1180 Interim safety and efficacy results of Victoria-01: a phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced/metastatic solid tumors
- 334 Phase 1 trial of GC101, an IL2free autologous tumor-infiltrating lymphocyte (TIL) therapy, in recurrent high-grade glioma: safety and preliminary efficacy
- Anchored Drill-Assisted Localization for Percutaneous Endoscopic Cervical Keyhole Surgery in the Treatment of Cervical Spondylotic Radiculopathy: A Technical Report and Preliminary Efficacy Evaluation
- Feasibility, Safety, and Preliminary Efficacy of Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease: A 12-Month Pilot Randomized Controlled Trial
BibTeX
@article{shi2026clinicogenomic,
title = {{Clinicogenomic characterization and targeted therapy efficacy in Chinese patients with NTRK fusion-positive thyroid cancer: a preliminary retrospective cohort study.}},
author = {Zhiyuan Shi and Yuan Liu and Yu Xiao and Xiang Wang and Lin Zhao and Yonghui Chen},
journal = {Translational cancer research},
year = {2026},
month = sep,
doi = {10.21037/tcr-2026-1605},
url = {https://europepmc.org/article/MED/42997742},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Clinicogenomic characterization and targeted therapy efficacy in Chinese patients with NTRK fusion-positive thyroid cancer: a preliminary retrospective cohort study.
AU - Zhiyuan Shi
AU - Yuan Liu
AU - Yu Xiao
AU - Xiang Wang
AU - Lin Zhao
AU - Yonghui Chen
PY - 2026
DA - 2026/09/28
JO - Translational cancer research
DO - 10.21037/tcr-2026-1605
UR - https://europepmc.org/article/MED/42997742
AB - Neurotrophic receptor tyrosine kinase (NTRK) fusion-positive thyroid cancer is a rare but highly aggressive malignancy. These tumors exhibit potential responsiveness to TRK-inhibitor therapy; however, real-world clinical data in Chinese populations remain scarce, and clinical management for radioiodine-refractory cases remains incompletely defined. This study aims to characterize the clinicopathological features of Chinese patients and to evaluate the efficacy and safety of the NTRK targeted agent. A single-center retrospective analysis was conducted. Sixteen patients were identified from 253 thyroid cancer patients who received next-generation sequencing from January 2022 to March 2025 at our institution. Exclusion criteria included insufficient pathological material and incomplete clinical follow-up records. Baseline clinical, pathological, genomic, and treatment-related variables were retrospectively abstracted from medical records. Follow-up was performed via clinical visits and serial imaging examinations to assess treatment responses and adverse events. The age range of the 16 patients was 6-55 years, and the pathological diagnosis of all tumors was primary papillary carcinoma. Children (n=10) and female patients (n=11) accounted for the majority of the cohort. Distant metastases were present at initial diagnosis in 12 patients, among whom pulmonary metastasis was observed in 11 cases. All 10 patients with NTRK3 fusions harbored the ETV6 fusion partner, whereas common fusion partners for NTRK1-positive tumors included TPM3, IRF2BP2, and SFPQ. Postoperative radioactive iodine (RAI) treatment yielded poor responses, and radioiodine resistance developed frequently. Larotrectinib produced favorable clinical outcomes in patients with RAI-refractory disease and induced tumor cell redifferentiation in one adolescent patient, with no severe adverse reactions. This disease predominantly affects young Chinese patients and is characterized by strong invasiveness and frequent RAI resistance. Encouraging therapeutic responses were observed in TRK inhibitor-treated subgroup.
SN - 2218-676X
SN - 2219-6803
ER -